Research Suggests Cannabis Cures?

So the long awaited Cannabis Live Drug trial is soon  to be aired on Channel4.   The Ecstasy drugs trial which ran sometime in 2012 was really great fully informed an well put together. Its consisted of giving participants drugs and or a placebo an monitoring there reactions. The same is to happen for cannabis. Along with having a live audience & the use of social media, It really is been set up for all to try an take part. Two of the world’s leading experts on the effects of illegal drugs on the brain, psychopharmacologists Professor Val Curran from UCL and Professor David Nutt from Imperial College will follow the trial as its conducted at University College London. In reality its nice to get a clear view on the drugs we be consuming.   I have no exact date on air time as of yet but I can tell you the participants will be using old style cannabis resin, “skunk” and a placebo and then undergo MRI scans and a variety of cognitive tests to assess the affects on memory and on

The purpose of this study was to evaluate the use of a vaporization system (the Volcano; VAPORMED® Inhalatoren) as a “smokeless” delivery system for inhaled marijuana. The study looked at heating marijuana to form a vapor and then comparing drug levels in the blood to those obtained from smoking an identical amount of marijuana from a cigarette. In addition, we compared the tolerability of the two methods and measured expired carbon dioxide to evaluate whether the vaporizer reduces exposure to respiratory toxins. Eighteen healthy subjects were recruited and admitted to the inpatient ward of the General Clinical Research Center (GCRC) at San Francisco General Hospital to investigate the delivery of marijuana by vaporization compared to marijuana smoked in a standard cigarette. One dose (1.7, 3.4, or 6.8% tetrahydrocannabinol) and delivery system (smoked marijuana cigarette or vaporization system) was randomly assigned for each of the six study days. The analysis suggests that the

Treatment options for neuropathic pain have limited efficacy and use is fraught with dose-limiting adverse effects. The endocannabinoid system has been elucidated over the last several years, demonstrating a significant interface with pain homeostasis. Exogenous cannabinoids have been demonstrated to be effective in a range of experimental neuropathic pain models, and there is mounting evidence for therapeutic use in human neuropathic pain conditions. This article reviews the history, pharmacologic development, clinical trials results, and the future potential of nonsmoked, orally bioavailable, nonpsychoactive cannabinoids in the management of neuropathic pain http://www.ncbi.nlm.nih.gov/pubmed/25160710?dopt=Abstract http://www.ncbi.nlm.nih.gov/pubmed/19789075

The full results of this study appear in the February 13, 2007 issue of the journal Neurology . Below is a brief summary of these results. Dr. Abrams and the Community Consortium conducted a study to evaluate the safety and effectiveness of smoked marijuana to treat pain caused by HIV-related peripheral neuropathy (injury to the nerves that supply feelings to your arms and feet). The study evaluated whether marijuana had an effect on pain relief. Marijuana was compared to a placebo; a cigarette that smells and tastes like marijuana but has no active ingredients (THC). The study evaluated both ongoing neuropathic pain (clinical pain) and temporary pain induced by applying heat and capsaicin (ingredient that makes red peppers hot) cream to a small area of the skin (experimental pain). Fifty-five patients were randomized and 50 completed the entire trial. Smoked marijuana reduced daily pain by 34% compared to 17% with placebo. The study concluded that 52% of patients who smoked m